Claudia Rinciog, MSc
Claudia is a Health Economics Associate Director. Since joining Symmetron in 2013, she specialises in evidence review and economic modelling in many disease areas including bipolar disease, rheumatoid arthritis, obesity, oncology, Parkinson’s disease, cardiovascular and pulmonary disease. She has supported submissions to reimbursement authorities in Europe and North America, and developed poster presentations for international conferences and manuscripts for peer-reviewed publications. Claudia graduated summa cum laude from Lafayette College in Easton, Pennsylvania, with a double degree in Biochemistry (BSc) and Economics (BA). As part of her senior year Economics thesis, she performed a regression analysis on the impact of household HIV status on the economic well-being of households in Zambia. After graduation, Claudia pursued an MSc in International Health Policy and Health Economics at London School of Economics and Political Science (LSE). As part of her LSE dissertation, Claudia interned at Medtronic in Tolochenaz, Switzerland, where she performed an explanatory statistical analysis of aortic valve replacement hospital episodes in the NHS from 2000 to 2010.
Rinciog C, Diamantopoulos A, Gentilini A, Bondue B, Dahlqvist C, Froidure A, Wuyts WA, Soulard S. Cost-effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics, 2020; 4:449-458.
Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. J Med Econ 2014 Jul;17(7):508-19.
Rinciog C, Myrén KJ, Aldén M, Diamantopoulos A, LeReun C. An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC). Value Health. 2014 Nov;17(7):A616-7.
Azorin JM, Sawyer L, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, et al. Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes. Value in Health. 2013;16(7):A549.
Buettner KM, Rinciog CI, Mylon SE. Aggregation kinetics of cerium oxide nanoparticles in monovalent and divalent electrolytes. Colloids and Surfaces A: Physicochemical and Engineering Aspects. Volume 366, Issues 1–3, 20 August 2010, Pages 74-79
Rinciog C, Sawyer L, Diamantopoulos A, Elkind M, Reynolds M, Tsintzos S, Ziegler PD, Quiroz M, Wolff C, Witte KK. Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK. ISPOR Europe 2018. Barcelona, Spain. November, 2018
Diamantopoulos A, Rinciog C, Forsey J, Glencorse M, Rizzo E, Murphy J. Vagus nerve stimulation for treatment-resistant depression: a budget impact analysis in England. ISPOR Europe 2018. Barcelona, Spain. November, 2018
Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y. Cost-effectiveness of nintedanib in idiopathic pulmonary fibrosis in the US. AMCP NEXUS 2018. October 22-25, 2018
KK. Witte, MSV. Elkind, M. Reynolds, SI. Tsintzos, PD. Ziegler, ME. Quiroz, C. Wolff, C. Rinciog, L. Sawyer, A. Diamantopoulos. Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stroke risk in a high-risk population in the UK. ESC Congress, 25-29 August 2018, Munich, Germany.
Tritaki G, Souliotis K, Bouros D, Papageorgiou I, Diamantopoulos A, Rinciog C, Schmidt U. Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system. ISPOR 19th Annual European Congress. Vienna, Austria. October, 2016